INTRODUCTION

Foxp3
+
CD4
+ regulatory T (Treg) cells are central to the maintenance of immunological homeostasis and tolerance in the T lymphocyte compartment (Sakaguchi et al., 2006) . This role is exemplified by the devastating lymphoproliferation and multiorgan autoimmunity that occur in mice or humans deficient in this population, whether through the carrying of spontaneous mutations (scurfy mice, IPEX patients) (Ziegler, 2006) or through experimental lineage ablation . A distinct geneexpression signature characterizes Foxp3 + Treg cells (Fontenot et al., 2005; Huehn et al., 2004; Herman et al., 2004; Hill et al., 2007) . Foxp3 plays an important role in determining this signature but is not the master regulator it was once thought to be, because it is neither sufficient to elicit the full Treg cell genomic profile nor strictly necessary for generation of the lineage (Gavin et al., 2007; Lin et al., 2007; Hill et al., 2007) . Most of the Treg cells present in lymphoid organs of normal mice are generated in the thymus (Hsieh et al., 2006; Pacholczyk et al., 2006; Wong et al., 2007a) , and the specific TCR repertoire that distinguishes them from conventional CD4 + T cells (Tconv) can be tracked from the thymus to peripheral lymphoid organs (Hsieh et al., 2006; Pacholczyk et al., 2006; Wong et al., 2007b) . In addition, mature CD4 + T cells from peripheral lymphoid organs can be converted to Foxp3 positivity in a variety of conditions: in chronic suboptimal stimulation by agonist peptide (Kretschmer et al., 2005; Apostolou and von Boehmer, 2004) , after exposure to orally administered agonist (Mucida et al., 2005; Coombes et al., 2007) , or during lymphopenia-driven homeostatic expansion . Finally, activation in the presence of the cytokines IL-2 and TGF-b in vitro can induce Foxp3 expression in naive Tconv cells, which then acquire some characteristics of Treg cells, including suppressive properties in some contexts (Chen et al., 2003; Fantini et al., 2004; Wan and Flavell, 2005) . In contrast, Foxp3 expression in TGF-b-induced Treg cells is unstable (Floess et al., 2007) ; these cells are not suppressive in all assays, and converted cells acquire only a partial segment of the genomic signature typical of Treg cells (Hill et al., 2007) . Most interesting in this context were the observations that dendritic cells (DCs) from gut origin, in particular a CD103 + population from the lamina propria (LP), can markedly enhance TGFb-induced conversion of CD4 + T cells to the Foxp3 + phenotype in vitro and that this effect can be ascribed to all-trans retinoic acid (RA), which also represses differentiation to an IL-17-secreting phenotype (Mucida et al., 2007; Sun et al., 2007; Coombes et al., 2007; Benson et al., 2007; Elias et al., 2008) . RA, the key metabolite of Vitamin A, is an important morphogen that affects the development and maintenance of a wide variety of tissues, as exemplified by the pleiotrophic abnormalities that appear in Vitamin-A-deficient embryos or adults (reviewed in Mark et al., 2006) . Concerning hematopoietic cells, RA can have general stimulatory effects on lymphocyte responses, possibly by inhibiting apoptotic pathways (Iwata et al., 2004) , and affects natural killer (NK) cell activity by modulating interferons and NK cell ligands (Abb et al., 1982a; Abb et al., 1982b; Cerwenka et al., 2000) . In addition, RA seems to play a predominant role in the homeostasis and homing of lymphoid populations of the gut-associated lymphoid tissue (GALT). It is synthesized in abundance by gut DCs (Iwata et al., 2004; Coombes et al., 2007) , induces the specific gut-homing molecules CCR9 and a4b7 integrin on T cells, and also promotes GALT-related functions in B cells (Iwata et al., 2004; Mora et al., 2006 ). RA's important role in controlling Foxp3 expression mediated by TGF-b also suggests that the GALT has evolved a specific system to maintain a balanced symbiosis between the gut flora and the immune system (Iwata et al., 2004; Mora et al., 2006; Mucida et al., 2007; Sun et al., 2007; Coombes et al., 2007; von Boehmer, 2007) .
RA receptors (RARs) belong to the family of nuclear hormone receptors and act as ligand-dependent transcriptional regulators. There are three subtypes of RARs (RARa, RARb, and RARg) (Chambon, 1994) , all of which bind all-trans RA at high affinity, but each has distinct developmental effects and genomic footprints. RARa and RARg are the predominant forms expressed in immunological cells (Purton et al., 2006) . More recently, it has been realized that RA can also serve as an activating ligand for the PPARb and PPARd receptors, with different effects on cell growth and apoptosis (Schug et al., 2007) .
In this context, it was clearly of interest to investigate the molecular mechanisms by which RA promotes Foxp3 expression mediated by TGF-b. Beyond their direct effects as transactivators, RARs also influence transcription by transrepression of AP-1 activity (Nicholson et al., 1990; Salbert et al., 1993; Chen et al., 1995; Altucci and Gronemeyer, 2001 ). This could conceivably affect Foxp3 expression in many ways: by altering signals induced by T cell costimulation (Wu et al., 2006) or by disturbing the competition between AP-1 and Foxp3 for NFAT binding (von Boehmer, 2007) and, therefore, any downstream events. Alternatively, liganded RARs could potentiate TGF-b signaling. The explorations reported here started from these premises but ended up with a rather different conclusion, unveiling a multicell interplay underlying RA's action.
RESULTS
Treg Cell Conversion and Homeostasis in RAR-Deficient Mice Three main nuclear receptors for RA have been described. Recent studies, using pharmacological inhibitors, have implicated RARa in RA-boosted Foxp3 induction (Schambach et al., 2007; Kang et al., 2007; Elias et al., 2008 ), but we felt it worthwhile to exploit genetically deficient mice to evaluate the individual contributions of the three receptors, as well as to assess the impact of the RA pathway on Treg cell populations in vivo. Thus, mice with loss-of-function mutations in Rara, Rarb, or Rarg (Chapellier et al., 2002c; Chapellier et al., 2002a; Chapellier et al., 2002b) were bred and analyzed. Purified CD4 +
Foxp3
À T cells from each of the mutant lines (or their control littermates) were stimulated in vitro by CD3 monoclonal antibodies together with WT splenic DCs and TGF-b, with or without RA. As expected, the proportion of Foxp3 + cells was boosted by RA in cultures from control littermates and from Rarb-deficient and Rarg-deficient mice, but the effect was completely abrogated by the Rara-deficient mutation ( Figures 1A and 1B) . Similarly, the induction of a4b7 integrin by RA was dependent on RARa ( Figure 1C ).
To investigate the impact of this blockade of RA signaling on the selection and steady-state frequency of Treg cell populations in vivo, we analyzed CD4 + lymphocytes from the thymus, secondary lymphoid organs, and GALT for expression of Foxp3 and CD25 ( Figure 1D ). the latter with or without 10 nM RA. The gene-expression profiles were obtained from purified T cell populations, with Foxp3-eGFP reporter mice used as donors. We focused particularly on the transcripts that constitute the robust ''Treg cell signature,'' derived from multiple data sets in a previous study (Hill et al., 2007) . In the graphs of Figure 2A , the expression profiles of Foxp3 + cells generated with TGF-b and LP DCs versus RA supplementation are compared in parallel to those from Foxp3 + cells generated simply with TGF-b and splenic DCs, a condition that leads to less conversion ). A direct comparison of transcripts affected by RA or LP DCs showed a clear parallel, supporting the notion that the ability of LP DCs to enhance Foxp3 expression is due to the production of RA ( Figure S1 , available online). Thus, the presence of RA did appear to slightly reinforce the Treg cell gene-expression signature. But did it promote complementation of the ''holes,'' i.e., those transcripts normally (Hill et al., 2007) ? This question was addressed by the signatureMatch analysis of Figure 2B . This algorithm is designed to test how well a signature is achieved in test populations. It uses normalized expression values that are then standardized relative to two reference populations that define the expression minima and maxima for each transcript of the signature (here ex vivo Treg and Foxp3 À Tconv cells, pops. 1 and 2). In agreement with our previous report, in vitro activation in the presence of IL-2 (pop. 3) induced a substantial fraction of the Treg cell signature, and the addition of TGF-b (pop. 4) brought forth only a minor subset of Treg cell signature transcripts (mainly in the TGF bracket). Although there was an additional impact of LP DCs in the cultures (pop. 5), partially mimicked by Sp DCs + RA (pop. 7), much of the Treg cell signature transcripts remained at the basal level of Tconv cells. Thus, the ''holes'' in the signature elicited by activation in the presence of TGF-b largely persist in spite of RA. The FoldChange plots of Figure S2 confirmed this impression, and there were substantial changes in only a small number of Treg cell signature genes. This inability of RA to complement the partial effect of TGF-b on the Treg cell signature is also evident from the representation of Figure 2C , which compares the effect of RA (in the presence of TGF-b) to the Treg cell profile: only a few genes of the Treg cell signature were directly affected in any appreciable manner by RA (e.g., Nrp1, P2rx7).
Most of the changes elicited by RA were independent of the Treg cell signature, a conclusion bolstered by the plot of Figure 2D , which compares the effects of RA in Foxp3 + cells versus in cells remaining Foxp3 À in those cultures: RA-responsive transcripts were very similar in both cell types. The RA signature (listed in Tables S1 and S2) included some of the transcripts one expects to be induced, such as Ccr9 and Itga4 (a4 integrin), but also some repressed transcripts. It did not show any substantial overlap with the ''TGF-b signature,'' i.e., the transcripts affected by TGF-b treatment independently of Treg cell conversion (Hill et al., 2007) , indicating that RA does not enhance conversion by increasing the intensity of TGF-b signaling. In contrast, the observation that the IL-6 receptor was downregulated by 75 percent was quite suggestive because IL-6, in the presence of TGF-b, promotes the expression of IL-17, while inhibiting that of Foxp3 (Veldhoen et al., 2006; Bettelli et al., 2006; Mangan et al., 2006; Stockinger and Veldhoen, 2007) .
IL-6 Is Only a Minor Player in RA's Action
The repression of IL-6Ra by RA observed in the gene-expression profiles suggested a mechanism for RA's action: because IL-6 inhibits the induction of Foxp3, RA might simply be reducing the sensitivity of naive T cells to inhibition by IL-6. We first confirmed by flow cytometry that the alpha chain of IL-6R was indeed repressed by RA ( Figure 3A ; over six experiments, the mean fluorescence intensity dropped from 526 ± 116 to 255 ± 81, p < 0.001). This regulation of IL-6Ra expression was also lost when cells from Rara À/À mice were tested ( Figure 3B ). Under our culture conditions, addition of recombinant IL-6 did have the expected inhibitory effect on Foxp3 expression, and this influence was partially reversed by RA, consistent with the notion that RA might help to relieve the inhibition by IL-6 ( Figure 3C ). In contrast, RA was still very effective in cultures of cells from IL-6-deficient mice; if anything, its influence was even stronger than that in cultures from WT mice ( Figure 3D ). Thus, an inhibition of IL-6 action, although it may partially contribute to RA's impact on Foxp3 expression, particularly in IL-6-rich environments, cannot be the main mechanism through which RA promotes TGF-b-mediated Foxp3 expression.
RA Acts Indirectly on Treg Cell Conversion
The rather limited impact of RA on transcriptional profiles of converted Treg cells raised the possibility of an indirect effect; of RA acting on something other than the responding cells. This hypothesis emerged to the forefront by a serendipitous observation. In experiments designed to test the effect of RA on isolated CD4
+ T cell subsets, we observed that the enhancing effect of RA was lost when the fully naive fraction of CD4 + cells (purified as CD44 lo CD62L hi ) were used as responders ( Figure 4A ), rather than CD4+ T cells from unfractionated splenocytes (Figure 4B) . Also apparent in these experiments was that purified naive CD4 + cells gave rise to a higher proportion of Foxp3 + convertants when cultured alone than when cultured as part of unfractionated splenocytes (compare the left panels of Figures 4A and 4B) . The insensitivity of naive CD4 + cells to RA
was not due to a saturating response to TGF-b, given that it was also observed through suboptimal doses of TGF-b (Figure 4C) . Similarly, the conversion of purified naive cells could not be boosted through a range of RA doses ( Figure 4D ). This lack of response did not mean that purified naive CD4 + T cells were refractory to RA, given that CCR9 and the a4b7 integrin were induced effectively in these cells by RA exposure (not shown).
These data suggested that the increased generation of Foxp3 + cells in response to RA in these cultures of unseparated splenocytes might represent the lifting of an inhibition imparted by other cells, a dampening lifted equally by RA or by purification of the naive responder cells. It seemed likely that the inhibitory cell might also be a CD4 + T cell, given that it was clearly possible to obtain strong responses to RA when whole CD4 + populations were used as responders to TGF-b (as in the experiments of Figures 1 and 2 , and as in all of the initial descriptions of RA's effect [Mucida et al., 2007; Lufkin et al., 1993; Coombes et al., 2007; Benson et al., 2007; Elias et al., 2008] ). This inhibitory population would then be predicted to have a CD44 hi memory phenotype and would thus be lost during the purification of naive responder cells. We directly tested this hypothesis by the reconstitution experiments depicted in Figure 5 , in which CD4 + cells were purified as CD44-negative or CD44-positive (each identifiable through CD45 allotypes so as to track their fate after culture) and admixed in stimulation cultures supplemented or not with RA. The induction of Foxp3 in naive cells was clearly inhibited by coculture with an equal number of CD44 hi cells, an inhibition reversed by the addition of RA ( Figure 5A ; several experiments tabulated in Figure 5B ). This inhibitory effect of CD44 hi cells (hereafter referred to as ''counterconversion'' for brevity), as well as its reversal by RA, could be titrated through a range of cell ratios ( Figure 5C ). This dose-response range was compatible with the results obtained with whole CD4 + cells (e.g., Figure 4 ), in which the CD44 À /CD44 + ratio was approximately 4. We then asked how CD44 hi memory T cells influence the TGFb-induced conversion of naive T cells, the production of a soluble factor being the most likely candidate. Culture supernatants from Figure 5A (anti-CD3 and anti-CD28 beads, TGF-b) were indeed able to mediate the inhibition of Foxp3 induction (although this dampening by supernatants was never quite as effective as when cells were added directly-compare Figures 5C and 5D ). Preliminary time-course analyses showed that production of the inhibitory factor(s) required stimulation of the CD44 hi population, peaking at 48 hr of culture (not shown). Thus, the impact of CD44 hi cells can be explained, at least in part, by the production of soluble inhibitors. This observation prompted us to ask how RA affects counterconversion activity. Conceptually, RA might prevent the production of inhibitory factors by CD44 hi cells, or it might decrease the sensitivity of responder naive cells. These two alternatives were tested in the experiments illustrated in Figures 5E and 5F . Treatment of the responder naive cells with RA had no impact on their susceptibility to inhibitory supernatant ( Figure 5E ). In contrast, treatment of the CD44 hi population did reduce the production of inhibitory factor(s) in the supernatants ( Figure 5F ).
As an independent confirmation that RA signaled through the CD44 hi population, rather than through the naive converting cells themselves, we exploited the identification of RARa, the primary receptor in this context, and conducted mixed cell experiments using naive or memory populations from Rara À/À mice or congenically marked wild-type (WT) mice ( Figure 5G ). Under these conditions, expression of Foxp3 in naive cells from Rara À/À mice could still be increased by RA. In contrast, RA was without effect when memory cells from Rara À/À mice were cocultured with WT naive cells. As expected, the genotype of the naive T cells was immaterial ( Figure 5G ). Thus, the primary mode of action of RA in enhancing the conversion to a Foxp3 + phenotype appears to be through the reduction of inhibitory factors produced by CD44 hi cells.
Counterconversion Results from Synergistic Cytokine Action
We then sought to identify the soluble factor(s) mediating counterconversion. Such a factor should have two characteristics: be produced by CD44 hi CD4 + cells and be reduced by RA treatment. Triplicate microarray profiles were generated on CD45-allotype-marked CD44 hi cells in stimulated cocultures prepared exactly as in Figure 5 , and these were compared with or without RA treatment. The results are displayed on the Expression versus FoldChange plot of Figure 6A , in which Gene Ontology identifiers were used for identifying cytokines and proteins released in the extracellular space (shown as red dots). Several factors immediately stood out in this analysis, matching criteria of both transcript abundance and repression by RA: IL-4, IL-9, IL-10, IL-21, and Interferon-g (IFN-g ). This analysis also confirmed the RA responsiveness of these cells, given that RA-responsive transcripts identified in Figure 2 were also found differentially expressed in CD44 hi cells (i.e., Itga4 and Ccr9). In contrast, the vast majority of secreted proteins were unaffected by RA or were even induced (e.g., granulin). Counterconversion was not likely to be mediated a gene that is at the same or a lower level than that found in an ex vivo Tconv cell. Numbers to the right of the diagram show the average score for each group across the entire signature. In order to confirm the regulation of expression of some of these cytokines by RA, we performed intracellular staining of the memory cells (identified in the cocultures as CD45.2 + ) after activation for 48 hr. Clear reductions in IL-10 and IL-4 production were evident in memory T cells treated with RA ( Figure S3 ). Somewhat surprisingly, we did not see the same trend for IFN-g, possibly due to a more complex posttranscriptional regulation. Notably, none of these cytokines were detected in naive CD44 À T cells cultured under the same conditions (not shown).
We then tested the effect of these candidate cytokines on TGF-b-induced conversion of naive CD4 + cells ( Figure 6B ). IL-9 and IL-10 had no effect. IL-21 was inhibitory as expected, but only at relatively high doses. IFN-g had a modest effect, but IL-4 led to a marked decrease of Foxp3 expression, consistent with recent studies (Wei et al., 2007; Mantel et al., 2007) . Antibody-blockade experiments were performed for determining which of these cytokines played the most important part in counterconversion in coculture experiments ( Figure 6C ). Blocking IL-21 or IFN-g individually had little or no effect, but anti-IL-4 antibodies had a significant impact on counterconversion activity (the importance of IL-4 was also apparent from the use of CD44 hi cells from Il4 À/À mice; Figure S4 ). Pairwise combinations of antibodies had little more effect than did each alone, but blockade of all three cytokines was more effective at eliminating counterconversion activity, albeit still incompletely ( Figure 6C ). It should also be noted that these blocking antibodies did not affect Foxp3 expression in cultures with naive T cells only, paralleling the insensitivity to RA that was seen (data not shown).
This result prompted us to further explore whether these cytokines act synergistically to inhibit Foxp3 expression by adding them back to conversion cultures of purified naive T cells at suboptimal doses ( Figure 6D ). At the doses used, IFN-g and IL-21 had little effect on their own and IL-4 lead to only a partial reduction in Foxp3 expression. Limited synergy was seen when cytokines were added in pairs; for example, IL-21 enhanced the inhibitory effects of IFN-g and IL-4. The largest reduction of Foxp3 expression was seen when all three cytokines were added at once, confirming their three-way synergy.
Thus, CD44 hi memory T cells release of a set of cytokines that inhibit TGF-b-driven Foxp3 expression. Their effect seems to be elicited by their combined and synergistic action, rather than by any of them alone, and RA inhibits the transcription of the whole panel.
RA Acts Indirectly on Antigen-Specific Conversion in GALT
To verify the in vivo relevance of the indirect mode of RA action demonstrated in vitro, we exploited the known role of RARa in the process, asking how the same WT CD4 + T cells would convert when transferred into WT or Rara À/À hosts. We used as a model Foxp3-negative OT-II T cells transferred into hosts also fed with oral ovalbumin. This model of in vivo antigen-specific conversion is restricted to the GALT, because conversion does not occur in subcutaneous lymph nodes or in spleen . Consistent with previous findings, transferring OT-II Rag1 À/À T cells (identifiable with a CD45.1 allotype and devoid of any detectable Foxp3 + cells) to either WT or Rara À/À hosts led to detectable conversion in both the lamina propria and the mesenteric lymph nodes of ova-fed mice ( Figure 7A ; as expected, no conversion was observed in the spleen or other lymph nodes); OT-II cells in WT recipients showed a 2-fold higher proportion of Foxp3-positive cells compared to those in Rara À/À hosts ( Figure 7B ). These data provide direct evidence that RA signaling via RARa affects Foxp3 induction in vivo in an indirect manner, through cells other than the naive CD4 + cells.
DISCUSSION
This study set out to elucidate the molecular mechanisms by which RA promotes the TGF-b-induced conversion of naive 
CD4
+ T cells to the Foxp3 + phenotype. Perhaps surprisingly, we did not observe major effects of RA on the responding cells. There was no enhancement of TGF-b signaling and no complementation of the Treg cell transcriptional signature, and the consequences of RA treatment on gene expression were relatively modest and largely shared between Foxp3-positive and Foxp3-negative cells in the same cultures. Instead, the data point to a rather different mode of action, in which RA counteracts the dampening effects of inhibitory populations whose existence was revealed by cell fractionation and complementation analyses. RA's activity was entirely mediated by RARa, which provided a useful experimental handle for confirmation of this indirect effect through crisscross experiments, in vitro and in vivo.
The use of purified CD4 + cells in the assays allowed us to discern the indirect effect of RA and the impact of counterconversion mediated by CD44 hi cells. In contrast, the ability of RA to repress IL-6Ra in naive T cells, which would reduce their susceptibility to inhibition by IL-6, also suggests the possible existence of direct effects. Although this direct effect appeared of secondary importance in our culture conditions, it may be more prominent in some in vivo situations, where IL-6 made by non-T cells may be more important. RA would thus safeguard TGF-b-induced conversion in several settings. An indirect effect of RA is compatible with the observation made by most groups that the compound has no effect whatsoever in the absence of TGF-b, which is understandable if it serves to relieve a repression rather than to directly promote conversion. That RA would interact with inhibitory cells is also compatible with the fact that there was substantial variability in the baseline efficacy of conversion (as noted by Benson et al., 2007) : most likely, the actual proportion of CD44 hi cells in the input population varied between donor pools. The conditions used for these cultures (engagement of CD3 and/or CD28, IL-2 supplementation, DCs) were conducive to cytokine production, and one can conceive of how small experimental variation might affect counterconversion. In fact, the nature of the activating stimulus may modulate the efficacy of RA in enhancing TGF-b-driven Foxp3 expression.
It is currently unclear whether counterconversion may also affect other modes of T cell differentiation elicited by TGF-b. In these cocultures, even with high concentrations of T cell-derived IL-21, we found no evidence for IL-17 production at the protein or mRNA level. Thus, there is clearly more than a dichotomous set of possible outcomes (Foxp3 or IL-17 expression) for naive T cells stimulated with TGF-b.
The ability of CD4 + Tconv cells to convert to a Foxp3 + phenotype when stimulated in a TGF-b-rich environment has been proposed as a means for achieving a balanced and regulated response, particularly in mucosal areas, such as the GALT, where peaceful coexistence (if not actual tolerance) must be achieved with the intestinal commensal flora. The ability to generate Treg cells when intestinal homeostasis is threatened is thus desirable, but it is also important that the system limit the potential for a ''runaway'' conversion to Treg cell phenotypes, which would overly suppress needed responses. The existence of a counterconversion pathway would be a logical means for controlling this potential; a balance between TGFb-fueled drive to conversion and counterconversion activity. In this context, RA would serve as an external modulator of this balance. It is provided by a third-party cell, and one can conceive of the DCs acting as sensors and integrators of local microbial challenge and inflammatory responses, influencing the conversion/ counterconversion balance by releasing variable amounts of RA. The particular ability of gut DCs to produce RA (Iwata et al., 2004; Coombes et al., 2007) is clearly in line with such a notion. Intriguingly, RA has little to no influence on the selection of Treg cells in the thymus, nor on their overall proportions in secondary lymphoid organs, as evidenced by the normal Treg cell populations in Rara-deficient mice. This is compatible with a view in which RA-influenced conversion of conventional CD4 + T cells to a Foxp3 + phenotype represents a focused adaptation, involving only particular reactivities or locations, but overall homeostatic control of Treg cell populations falls under a different control, such as the supply of trophic cytokines. The dampening of Foxp3 induction by cytokines showed clear synergistic effects. IL-4 was the most active in this respect, but IL-21 and IFN-g clearly enhanced this ability, and they complemented each other in doing so. This synergy is unusual for IL-4 and IFN-g, which are usually antagonistic. It will be important to elucidate the signaling pathways involved, but one can imagine complex interactions wherein one cytokine induces the receptor or the signaling cascade downstream of the other.
It should also be pointed out that, although counterconversion can be mediated by cytokines in this synergistic fashion, soluble factors do not account for the whole effect of CD44 hi cells. Supernatants from CD44 hi cells were never quite as effective as the cells themselves, and inhibition of counterconversion with antibody combinations only incompletely reversed the inhibitory effect. Although these elements could be explained by focused release and action of cytokines or by additional soluble mediators, they also suggest that cell-cell interactions may be involved in counterconversion.
What In fairness, although the concept of counterconversion is logical and has operational value, we do not know whether a dedicated ''counterconvertor'' population exists. Such a label does carry the teleological connotation of a distinct and identifiable population whose role (or one of whose roles) is to maintain the conversion or counterconversion balance. An alternative scenario is one in which there is no such uniquely identifiable population but rather a set of differentiated states that produce a set of cytokines that dampen TGF-b-mediated Foxp3 induction. This effect could be instilled in an antigen-or location-specific manner and perpetuate the dominance of effective T cell responses, by inhibiting the neogeneration of Treg cells, even in locations of Individual populations were tracked with the use of CD45.1 or CD45.2 congenic markers. Foxp3 expression in congenically marked populations was determined by FACS, and a representative experiment is shown.
(B) FACS analysis for Foxp3 expression in multiple experiments as described in (A) (n = 14-19). Statistically significant differences were determined by Student's t test.
strong TGF-b exposure. Whether one or several cell types affect counterconversion, it is striking that RA represses the entire inhibitory program.
EXPERIMENTAL PROCEDURES
Mice C57BL/6J (CD45.1 congenic), C57BL/6J, C57BL/6-H2g7, C57BL/6-Il6
, and C57BL/6-Il4 À/À mice were bred in the SPF Joslin facility or purchased from Jackson Laboratories. Rar-deficient mice (Chapellier et al., 2002a; Chapellier et al., 2002b; Chapellier et al., 2002c) were bred in the SPF facility at IGBMC, whereas Foxp3-eGFP reporter mice (Bettelli et al., 2006) and OT-II Rag1 À/À (CD45.1 congenic) mice were bred in the SPF facility at NIAID.
Cells
Cells used for in vitro activation and in vivo transfer were obtained from spleen and lymph nodes or lamina propria of 6-to 8-wk-old mice. Unless otherwise noted, cells were sorted to obtain individual T cell or DC subpopulations. In Vitro Activation For conversion assays, T cells were activated with anti-CD3 and anti-CD28 beads (Dynal) at a concentration of one bead per cell in the presence of 20 U/ml recombinant human IL-2 (Proleukin, Chiron) and 10 ng/ml recombinant TGF-b (Peprotech), for 4 days in a 96-well plate. Naive CD4 + T cells were cultured at a concentration of 0.5 3 10 5 per well, or 0.25 3 10 5 per well when used in coculture assays. Memory CD4 + T cells were seeded at a 2:1 (memory:naive) cell ratio in coculture experiments (unless otherwise noted). Some cultures were also treated with all-trans RA (100 nM unless otherwise noted; Sigma), recombinant mouse IL-4, IL-6, IL-9, IL-10, IL-21, or IFN-g (at the indicated concentrations; Peprotech), or blocking antibodies specific for IL-6Ra, IL-4, IL-21, or IFN-g (5 mg/ml; R&D Systems purified LP or Sp DCs in the presence of anti-CD3 (1 mg/ml), TGF-b (3 ng/ml), IL-2 (5 ng/ml), and RA (10 or 100 nM) as described previously .
Cell Sorting and Flow Cytometry
In Vivo Conversion Assay OT-II RAG-1 À/À CD45.1 CD4 + T cells (0.5-1 3 10 6 per mouse) were transferred i.v. into either Rara À/À or WT littermate controls as described previously . The drinking water of recipient mice was supplemented with 1.5% ovalbumin and changed every 2 days. Mice were sacrificed 7 days after T cell transfer, and Foxp3 expression in CD45.1 + donor T cells was detected in skindraining lymph nodes, spleen, mesenteric lymph node, and the lamina propria.
Microarrays RNA was prepared from sorted cell populations as described previously (Trizol; Yamagata et al., 2004) . RNA was amplified for two rounds (MessageAmp aRNA, Ambion), biotin-labeled (BioArray High Yield RNA Transcription Labeling, Enzo), and purified with the RNeasy Mini Kit (QIAGEN). The resulting cRNAs were hybridized to M430 2.0 chips (Affymetrix). All cell populations analyzed were generated in duplicate or triplicate. Raw data were normalized with the RMA algorithm implemented in the ''Expression File Creator'' module from the GenePattern software package (Reich et al., 2006) . Data were visualized with the ''Multiplot'' module from GenePattern.
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